OBJECTIVES: We describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway, and Sweden over a 50-year period. DESIGN: Population-based survival study. METHODS: Relative 5-year survival data were obtained from the NORDCAN database for the years 1972-2021. RESULTS: In the first period 1972-1976, 5-year survival in TC in Finland, Norway, and Sweden was 90% or higher, but a strong negative step-wise age gradient was observed, which was worse for men than women. Over time, survival increased, and in the final period, 2017-2021, survival for all women and Danish men up to age 69 years was about 90% or higher and, for men from the other countries, only marginally lower. Even for older women survival reached 80%, for older men somewhat less. CONCLUSIONS: Age disadvantage in TC survival was for the most part corrected over the 50-year period, and the remaining task is to boost survival for the oldest patients.

Biomedical Center Charles University Medical School 32300 Pilsen Czech Republic

Biomedical Center Faculty of Medicine Charles University Pilsen Pilsen 30605 Czech Republic

Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki 00029 Helsinki Finland

Comprehensive Cancer Center Helsinki University Hospital 00029 Helsinki Finland

Department of Otorhinolaryngology Head and Neck Surgery Helsinki University Hospital University of Helsinki 00029 Helsinki Finland

Division of Cancer Epidemiology German Cancer Research Center Im Neuenheimer Feld 580 Heidelberg D 69120 Germany

Division of Pediatric Neurooncology German Cancer Research Center 69120 Heidelberg Germany

Hopp Children's Cancer Center 69120 Heidelberg Germany

Skin and Allergy Hospital Helsinki University Hospital University of Helsinki 00029 Helsinki Finland

Citace poskytuje Crossref.org